Evidence map›Paper›PMID 36454778›Full record

ArticlePloS one2022

Neutrophil/lymphocyte ratio and other blood cell component counts are not associated with the development of postmolar gestational trophoblastic neoplasia.

Antonio Braga, Ana Clara Canelas, Berenice Torres, Izildinha Maesta, Luana Giongo Pedrotti, Marina Bessel, Ana Paula Vieira Dos Santos Esteves, Joffre Amim Junior, Jorge Rezende Filho, Kevin M Elias and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Antonio BragaDepartment of Obstetrics and Gynecology, Postgraduate Program in Perinatal Health, Faculty of Medicine, Maternity School of Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-2942-6182
Ana Clara CanelasDepartment of Obstetrics and Gynecology, Postgraduate Program in Perinatal Health, Faculty of Medicine, Maternity School of Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil.
Berenice TorresDepartment of Obstetrics and Gynecology, Postgraduate Program in Perinatal Health, Faculty of Medicine, Maternity School of Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0003-1687-2666
Izildinha MaestaDepartment of Gynecology and Obstetrics, Botucatu Trophoblastic Disease Center of the Clinical Hospital of Botucatu Medical School, São Paulo State University - UNESP, Botucatu, São Paulo, Brazil.
Luana Giongo PedrottiHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
Marina BesselHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
Ana Paula Vieira Dos Santos EstevesDepartment of Obstetrics and Gynecology, Postgraduate Program in Perinatal Health, Faculty of Medicine, Maternity School of Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil.
Joffre Amim JuniorDepartment of Obstetrics and Gynecology, Postgraduate Program in Perinatal Health, Faculty of Medicine, Maternity School of Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil.
Jorge Rezende FilhoDepartment of Obstetrics and Gynecology, Postgraduate Program in Perinatal Health, Faculty of Medicine, Maternity School of Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil.
Kevin M EliasDepartment of Obstetrics, Gynecology and Reproductive Biology, New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Neil S HorowitzDepartment of Obstetrics, Gynecology and Reproductive Biology, New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Ross S BerkowitzDepartment of Obstetrics, Gynecology and Reproductive Biology, New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Universidade Federal do Rio de Janeiro · BRBrigham and Women's Hospital · USHospital Moinhos de Vento · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo relate preevacuation platelet count and leukogram findings, especially neutrophil/lymphocyte ratios (NLR) and platelet/lymphocyte ratios with the occurrence of gestational trophoblastic neoplasia (GTN) after complete hydatidiform mole (CHM) among Brazilian women.

methodsRetrospective cohort study of patients with CHM followed at Rio de Janeiro Federal University, from January/2015-December/2020. Before molar evacuation, all patients underwent a medical evaluation, complete blood count and hCG measurement, in addition to other routine preoperative tests. The primary outcome was the occurrence of postmolar GTN.

resultsFrom 827 cases of CHM treated initially at the Reference Center, 696 (84.15%) had spontaneous remission and 131 (15.85%) developed postmolar GTN. Using optimal cut-offs from receiver operating characteristic curves and multivariable logistic regression adjusted for the possible confounding variables of age and preevacuation hCG level (already known to be associated with the development of GTN) we found that ≥2 medical complications at presentation (aOR: 1.96, CI 95%: 1.29-2.98, p<0.001) and preevacuation hCG ≥100,000 IU/L (aOR: 2.16, CI 95%: 1.32-3.52, p<0.001) were significantly associated with postmolar GTN after CHM. However, no blood count profile findings were able to predict progression from CHM to GTN.

conclusionAlthough blood count is a widely available test, being a low-cost test and mandatory before molar evacuation, and prognostic for outcome in other neoplasms, its findings were not able to predict the occurrence of GTN after CHM. In contrast, the occurrence of medical complications at presentation and higher preevacuation hCG levels were significantly associated with postmolar GTN and may be useful to guide individualized clinical decisions in post-molar follow-up and treatment of these patients.

Indexed as

Gestational Trophoblastic DiseaseNeutrophilsBlood Cell CountBrazilCellular StructuresFemaleHumansLymphocytesPregnancyRetrospective Studies

Identifiers

PMID36454778
PMCPMC9714693
OpenAlexW4310506800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.